Evaluation of enalapril combined with diltiazem ER in patients with stage 3-4 essential hypertension

Clin Exp Hypertens. 1998 Jan;20(1):41-52. doi: 10.3109/10641969809053205.

Abstract

Enalapril combined with an extended-release formulation of diltiazem was evaluated in a 12-week multicenter trial of 112 patients with Stages 3-4 essential hypertension. Patients were randomized to once daily therapy with enalapril 5 mg plus diltiazem ER 120 mg or 180 mg. Dosages could be titrated and other antihypertensive agents added for blood pressure control. Efficacy was assessed with sitting blood pressures at trough (24 hours postdose). Overall, there was a decrease of -21.7/-18.4 mmHg. Patients responding to enalapril/diltiazem ER alone had a reduction of -15.0/-16.3 mmHg. Of all patients, 70% achieved a trough sitting diastolic blood pressure of < 95 mmHg. Common drug-related adverse experiences were headache, dizziness, rash, and asthenia/fatigue. This once daily fixed-combination of enalapril/diltiazem ER was generally well tolerated and effective when given alone or with other antihypertensives in Stage 3-4 hypertension.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antihypertensive Agents / adverse effects
  • Antihypertensive Agents / therapeutic use*
  • Diltiazem / adverse effects
  • Diltiazem / therapeutic use*
  • Disease Progression
  • Drug Therapy, Combination
  • Enalapril / adverse effects
  • Enalapril / therapeutic use*
  • Evaluation Studies as Topic
  • Female
  • Humans
  • Male
  • Middle Aged

Substances

  • Antihypertensive Agents
  • Enalapril
  • Diltiazem